Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
bluebird bio (BLUE)
NASDAQ:BLUE
Bluebird Bio (BLUE) Stock Price & Analysis
2,550 Followers
BLUE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.85 - $5.53
Previous Close$1.07
Volume3.98M
Average Volume (3M)8.31M
Market Cap
$206.23M
Enterprise Value$335.65M
Total Cash (Recent Filing)$174.29M
Total Debt (Recent Filing)$303.71M
Price to Earnings (P/E)-1.4
Beta1.35
Next Earnings
Aug 06, 2024EPS Estimate
-$0.43Last Dividend Ex-Date
Nov 05, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding109,336,211
10 Day Avg. Volume7,921,276
30 Day Avg. Volume8,309,979
Standard Deviation0.21
R-Squared0.05
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.55
Price to Sales (P/S)32.52
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.90
Enterprise Value/Gross Profit-51.80
Enterprise Value/Ebitda-3.85
Forecast
1Y Price Target
$3.97Price Target Upside278.10% Upside
Rating ConsensusHold
Number of Analyst Covering11
Bluebird Bio News
PremiumStock Analysis & Ideas
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
PremiumCompany Announcements
Bluebird Bio Faces Nasdaq Compliance Challenge and Delays
PremiumStock Analysis & Ideas
Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game?Bulls Say, Bears Say
Bulls Say
Coverage And Reimbursement AgreementsThe company has secured outcomes-based agreements with national commercial payers and is in discussions with agencies, expanding coverage for a significant portion of Medicaid-insured individuals, which may lead to increased access and demand for Lyfgenia.
Financial Performance And RevenueRevenue recognition for Lyfgenia is anticipated to begin, signalling a new era of financial growth for the company, bolstered by management's confidence in meeting their patient start guidance.
Product Launch And Market InterestWith the activation of 64 qualified treatment centers, there is a visible momentum building for the gene therapy Lyfgenia, which is further evidenced by the large number of patients registering for the bluebird support platform.
Bears Say
Financial PerformanceFinancial restatement for previous years has delayed the FY23 10-K and 1Q24 10-Q filings, with no specific timelines provided for resolution.
Market SentimentThe restatement of 2022/23 financials for treatment of leases is a blow to investor confidence for BLUE.
Revenue ConcernsProduct revenue for the first quarter was below both estimates and consensus.
---
Ownership Overview
4.95% Insiders
11.40% Mutual Funds
24.98% Other Institutional Investors
58.67% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BLUE FAQ
What was bluebird bio’s price range in the past 12 months?
bluebird bio lowest stock price was $0.85 and its highest was $5.53 in the past 12 months.
What is bluebird bio’s market cap?
Currently, no data Available
When is bluebird bio’s upcoming earnings report date?
bluebird bio’s upcoming earnings report date is Aug 06, 2024 which is in 81 days.
How were bluebird bio’s earnings last quarter?
bluebird bio released its earnings results on May 09, 2024. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.441 by $0.051.
Is bluebird bio overvalued?
According to Wall Street analysts bluebird bio’s price is currently Undervalued.
Does bluebird bio pay dividends?
bluebird bio pays a Notavailable dividend of $8.88 which represents an annual dividend yield of N/A. See more information on bluebird bio dividends here
What is bluebird bio’s EPS estimate?
bluebird bio’s EPS estimate is -$0.43.
How many shares outstanding does bluebird bio have?
bluebird bio has 192,741,940 shares outstanding.
What happened to bluebird bio’s price movement after its last earnings report?
bluebird bio reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.441. Following the earnings report the stock price went up 15.464%.
Which hedge fund is a major shareholder of bluebird bio?
Among the largest hedge funds holding bluebird bio’s share is Farallon Capital Management, L.L.C.. It holds bluebird bio’s shares valued at 3M.
---
Bluebird Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.97 (278.10% Upside)
$3.97 (278.10% Upside)
Blogger Sentiment
Bullish
BLUE Sentiment 90%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 925.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $26.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
---
BLUE Earnings Call
Q1 2024
0:00 / 0:00
---
BLUE Stock 12 Month Forecast
Average Price Target
$3.97
▲(278.10% Upside)
Technical Analysis
Best Analysts Covering BLUE
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+7.01%
reiterated a sell rating 8 days ago
Copying Salveen Richter's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +7.01% per trade.
---